Clostridioides Difficile Infection
43
15
17
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
4.7%
2 terminated out of 43 trials
84.6%
-1.9% vs benchmark
16%
7 trials in Phase 3/4
55%
6 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (43)
LMN-201 for Prevention of C. Difficile Infection Recurrence
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population
Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only Treatment
Evaluation of GeoHAI Implementation
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
Effect of Oral Microbiota on MDRO Decolonization
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
Safety and Tolerability of AZD5148 in Japanese Participants
Clostridioides Difficile: Understanding Responses and Treatment Effects
Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease
Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection